Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth.
Cohen
I
I
Rosen
D J
DJ
Altaras
M
M
Beyth
Y
Y
Shapira
J
J
Yigael
D
D
D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D010048:Ovarian Cysts / Q000139:chemically induced* / Q000473:pathology; D010053:Ovary / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D017697:Premenopause; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014463:Ultrasonography; D014591:Uterine Diseases / Q000139:chemically induced* / Q000473:pathology; D014599:Uterus / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology
D013629:Tamoxifen